Mar 15, 2022 / 07:20PM GMT
Hartaj Singh - Oppenheimer & Co. Inc., Research Division - Research Analyst
Great. Thank you, Andrew. Really appreciate it. Thanks, everyone, for joining us. We've gone towards the end of our first day of our Oppenheimer Healthcare Conference. We got Sarepta Therapeutics. And the CEO and the CFO of the company, Doug Ingram and Ian Estepan joining us today.
This is a company that we've gotten very bullish on recently, and part of that is just the tremendous amount of work the company has been doing in muscular dystrophies over the last 3, 4 years. Work that is really becoming very fulsome. So we're excited to have both Doug and Ian on here to talk about the company and all the projects ongoing.
So with that, welcome, gentlemen.
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you. Thanks for having us.
Hartaj Singh - Oppenheimer & Co. Inc., Research Division - Research Analyst
Great. And what we'll do, Doug, if you don't mind, give us about a 3- to 5-minute
Sarepta Therapeutics Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Feb 09, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers